This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Atrophy or Vaginal Diseases
and you are
between 40 and 80
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The primary objective of the study was to assess the long-term safety of 30- and 60-mg daily doses of ospemifene in the treatment of Vulvar and Vaginal Atrophy (VVA) in postmenopausal women with an intact uterus.

Provided treatments

  • Drug: Ospemifene (Dose 1)
  • Drug: Ospemifene (Dose 2)
  • Drug: Placebo

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01585558. The sponsor of the trial is Shionogi and it is looking for 180 volunteers for the current phase.
Official trial title:
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus: A 40 Week Randomized, Double Blind, Placebo Controlled, Follow-Up to Protocol 15-50310.